Skip to content

Every day, 6am to midnight

Mounjaro (tirzepatide) in Malta

Mounjaro contains the active substance tirzepatide, which acts on two hormone receptors at once: GIP and GLP-1. It is authorised for type 2 diabetes and for weight management, so the same name covers two rather different treatment situations. It is a medicine subject to medical prescription, and the situation, the dose and the schedule all belong to a doctor. This page sets out the authorised uses, the doses in the product information, the side effects and what we can and cannot do.

What Mounjaro is and which active substance it contains

Mounjaro contains tirzepatide, which the product information describes as a long-acting agonist of two receptors, GIP and GLP-1. Both receptors belong to hormones involved in regulating blood sugar, and both are found in the areas of the brain important to appetite. Older medicines in the group, such as semaglutide and liraglutide, act on the GLP-1 receptor only.

Mounjaro is authorised centrally for the European Union, and its product information is published by the European Medicines Agency. It is given as an injection under the skin once a week, in strengths from 2.5 mg to 15 mg. It is not a tablet and it is not insulin.

Because the same name covers two authorised situations, it matters which one your own treatment is about. Medicines acting on the GLP-1 receptor only are described on the semaglutide page and the liraglutide page. The group as a whole is compared in our overview of GLP-1 medicines. Choosing between them is a medical decision, not a matter of preference.

The two authorised situations

In type 2 diabetes, Mounjaro is authorised for adults, adolescents and children aged 10 years and above whose diabetes is not well enough controlled, always together with diet and exercise. It can be used on its own when metformin is not suitable, or added to other diabetes medicines; that combination is what the doctor decides on. The diabetes indication covers type 2 diabetes only; type 1 diabetes and diabetic ketoacidosis are not what this medicine is intended for.

In weight management, it is authorised for adults with a body mass index (BMI) of 30 or more, or of 27 to under 30 with at least one weight-related condition, such as high blood pressure, disturbed blood fats, obstructive sleep apnoea, cardiovascular disease, prediabetes or type 2 diabetes. It is used together with a reduced-calorie diet and more physical activity, not instead of them. Its safety and efficacy for weight management have not been established under 18 years. What the BMI figures mean is explained in our guide to obesity and BMI.

The two situations differ in what the doctor monitors, which other medicines need adjusting and what counts as success. Where a doctor prescribes a medicine outside its authorised use, that is a decision that has to be justified and supervised, and no questionnaire can substitute for it.

How tirzepatide works

Tirzepatide increases the release of insulin in a glucose-dependent way, meaning mainly when blood sugar is raised, and it lowers the level of glucagon, the hormone that pushes blood sugar up. According to the product information, it also reduces energy intake and appetite by increasing the feeling of fullness and decreasing hunger.

Because the insulin effect depends on blood sugar, low blood sugar is not typical when the medicine is used on its own. The risk rises when it is combined with insulin or with a sulfonylurea, and in those combinations the doctor may lower the doses of those medicines.

Tirzepatide also slows the emptying of the stomach. That is one reason why digestive complaints are the most common side effects, especially while the dose is being built up. The action is long-lasting, so the medicine is injected once a week. The effect is judged by the doctor from measurements and laboratory results over a longer period, not from how one week goes.

Doses in the product information

The product information sets a fixed starting dose and the steps for raising it. The table summarises section 4.2; it is not an instruction, because your dose and the pace of the steps are set by the doctor.

StepWeekly doseWhen
Starting dose2.5 mg once a weekFirst 4 weeks
Second step5 mg once a weekAfter 4 weeks on 2.5 mg
Further steps, if neededIncreases of 2.5 mg (7.5 mg, 10 mg, 12.5 mg, 15 mg)After at least 4 weeks on the current dose
Maintenance in adults5 mg, 10 mg or 15 mgAs decided by the doctor
Maximum15 mg once a week in adults; 10 mg in children and adolescents treated for type 2 diabetesNot exceeded

Single-dose pen, vial and KwikPen

The product information covers three presentations with the same doses. Which one you are given depends on the prescription and the pharmacy, and the instructions for use in the package leaflet must be read before the first injection.

The medicine is injected under the skin of the abdomen or thigh, or into the back of the upper arm by another person, at any time of day, with or without meals. The injection site is changed with each dose. Do not share your pen with other people, even if the needle has been changed.

If a dose is missed, the product information says to inject it as soon as possible within 4 days; if more than 4 days have passed, skip it and take the next dose on the usual day. Do not use a double dose to make up for a forgotten one. The day of the week can be changed as long as there are at least 3 days between two doses. Do not stop using it without talking to the doctor: in type 2 diabetes, blood sugar can rise after stopping. After a longer break, ask the doctor how to restart rather than going straight back to your last dose.

PresentationWhat the product information says
Pre-filled pen, single-doseOne pen for one weekly injection, in each strength from 2.5 mg to 15 mg
Vial, single-doseOne vial for one injection; you are trained in the injection technique before using it
KwikPen, multi-dose penHolds 4 doses of one strength; discarded 30 days after first use, and may be kept below 30 °C during that time; contains benzyl alcohol (5.4 mg in each 0.6 ml dose)

Side effects and when to contact a doctor

The most frequently reported side effects are digestive, mostly mild or moderate: nausea, diarrhoea, vomiting, abdominal pain and constipation. Nausea, diarrhoea and vomiting are most frequent while the dose is being raised and decrease over time. Indigestion, bloating, burping, wind and reflux are also described. Smaller meals and eating slowly can help.

Other effects described include reduced appetite, tiredness, dizziness, low blood pressure, hair loss, a faster heart rate and reactions at the injection site. Gallstones and inflammation of the gallbladder are also listed, and in the weight management studies gallbladder events were linked with weight loss, so pain in the right upper abdomen is a reason to contact a doctor.

Vomiting and diarrhoea can lead to dehydration, which can worsen kidney function, so drink enough and tell the doctor early. Stop the medicine and seek medical help in the case of severe and persistent abdominal pain, especially spreading to the back and with vomiting, because acute pancreatitis is a recognised risk, or with signs of a severe allergic reaction such as swelling of the face, lips or throat and difficulty breathing. In an emergency, call 112.

Before any procedure under general anaesthesia or deep sedation, including a gastroscopy or a colonoscopy done under sedation, tell the team that you use this medicine: cases of pulmonary aspiration have been reported with medicines acting on the GLP-1 receptor, because food can stay in the stomach for longer than expected. Do the same for a procedure arranged at short notice.

If you have diabetic eye disease, any change in vision is a reason to contact your doctor rather than to wait: a rapid improvement in blood sugar has been linked with a temporary worsening of diabetic retinopathy. The full list of side effects is in the leaflet in your pack.

Pregnancy, contraception and breastfeeding

The product information recommends contraception for women who could become pregnant while using tirzepatide. It is not recommended during pregnancy. If you wish to become pregnant, or become pregnant, it is stopped, and it should be stopped at least 1 month before a planned pregnancy, because it stays in the body for a long time.

For combined contraceptive pills, the product information states that no change of dose is needed. Severe vomiting or diarrhoea can still make a contraceptive pill less reliable, so tell the doctor if it happens. Breastfeeding is something to raise with the doctor before use. We do not start this treatment in pregnancy, when you are planning a pregnancy or while you are breastfeeding.

Interactions, alcohol and when the medicine is not suitable

Slower stomach emptying can change how medicines taken by mouth are absorbed, especially at the start of treatment and after a dose increase. For most medicines this needs no change, but the product information recommends monitoring medicines with a narrow safety margin, such as warfarin and digoxin. Bring a complete list of what you take, including products bought without a prescription, supplements and herbal preparations.

The combination that needs most attention is insulin or a sulfonylurea at the same time, because the risk of low blood sugar is then higher and doses often need lowering; blood sugar self-monitoring is then needed to adjust them.

Alcohol changes blood sugar and makes digestive complaints worse. If you also use insulin or a sulfonylurea, a fall in blood sugar after alcohol can come late, often during the night. Discuss the amount with the doctor who is following your treatment.

The only contraindication in the product information is an allergy to tirzepatide or to an ingredient. Before prescribing, a doctor still checks for a past inflammation of the pancreas, severe disease of the digestive system including severe gastroparesis, gallbladder disease, diabetic eye disease and a family history of rare thyroid and endocrine disease.

Prescription status, cover and the price at the pharmacy

Mounjaro is a medicine subject to medical prescription: that is its classification in Annex II B of the EU product information. A pharmacy therefore supplies it only against a prescription, and the decision to prescribe belongs to a doctor after an assessment of your medical information.

The price of Mounjaro in Malta is set by the pharmacy and depends on the presentation and the strength, so we do not quote it, and the pharmacy is the place to ask. It is not an ePrescription and does not appear in myHealth; it is outside POYC and the Government Formulary List, and you pay for the medicine at the pharmacy in full. Our fee for the doctor's review is a separate item and never includes the medicine.

The Medicines Authority states that in Malta "all medicinal products are dispensed only from pharmacies". A pen offered outside a pharmacy may be falsified.

What happens online and what does not

Online, only the doctor's review takes place. A request for Mounjaro goes through our Weight Loss Treatment service, whether you are starting or continuing and whether the treatment is for weight management or for type 2 diabetes. You fill in a medical questionnaire about the medicine, your health and other medicines you take, and the doctor reviews it in writing.

If the doctor has questions, they ask them in writing in the chat in your account, and you get an email to let you know. There is no video call, no phone call and no live chat. We do not sell or send medicines, and no internet pharmacies have been established in Malta.

A first prescription is possible only where your answers show clear indications and no contraindications; the doctor may ask for measurements or recent results, may recommend that you see a doctor in person, and may decline. For some conditions, and in some individual cases, it is advisable to see a doctor in person; the doctor may recommend this.

If the doctor issues a prescription, you receive it as a PDF by email. You print it and bring it on paper to a pharmacy in Malta together with photo identification. Your prescription is issued in the standard EU cross-border format set out in Directive 2012/52/EU. A pharmacy in Malta may dispense it; the decision rests with the pharmacist. Take the prescription to a pharmacy within six months of the date on it; a prescription for an antibiotic cannot be dispensed more than ten days after its date of issue.

The fee covers the medical consultation, not the issuing of a document. If the doctor declines on medical or legal grounds, we refund the fee. If the doctor asks you for documents, you have at least 7 days to send them in and we send you a reminder; if you ask us, we agree a longer deadline. If the case still cannot be completed, we close the request, let you know and refund the fee in full.

Who reviews your request?

Every request is reviewed by one doctor: Damian Wojno, a doctor registered with the Polish Medical Chamber, licence no. 3211301. The doctor is not registered with the Medical Council of Malta. We do not prescribe opioids, benzodiazepines, Z-drugs, stimulants, gabapentinoids or medical cannabis. This is our own rule and goes further than the Maltese lists of controlled drugs. Tirzepatide is not affected by it.

Is Mounjaro prescription only in Malta?

Mounjaro has a central EU authorisation, and its product information (Annex II B) classifies it as a medicine subject to medical prescription. A pharmacy supplies it only against a prescription, because a doctor has to decide which situation is being treated, which dose to start at and which of your other medicines need adjusting. A review can also end in a refusal.

What doses does Mounjaro come in?

The strengths are 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg, injected once a week. Treatment starts at 2.5 mg for 4 weeks, then 5 mg, and further steps of 2.5 mg follow only after at least 4 weeks on the current dose. The maintenance dose in adults is 5 mg, 10 mg or 15 mg, and 15 mg is the maximum. Your own dose is set by the doctor.

Which side effects of Mounjaro are common?

Nausea, diarrhoea and vomiting are the most common and are most frequent while the dose is being raised. Indigestion, bloating, constipation, reduced appetite, tiredness, dizziness, hair loss and reactions at the injection site are also described. Severe abdominal pain spreading to the back, and pain in the right upper abdomen, are reasons to contact a doctor. The full list is in the leaflet for your pack.

How quickly does it work?

Treatment starts at the lowest dose and is raised in steps of at least four weeks, so the full dose is not reached at the beginning. The effect on blood sugar or on weight is judged by the doctor from laboratory results and measurements over a longer period, not from how one week goes.

Is alcohol allowed with Mounjaro?

Alcohol changes blood sugar and makes digestive complaints worse, so the combination is not neutral. If you also use insulin or a sulfonylurea, the risk of low blood sugar is higher and a fall often shows up at night. Discuss the amount with the doctor who is following your treatment.

Can Mounjaro be prescribed online?

The doctor can review a request for it through our Weight Loss Treatment service, also where the treatment is for type 2 diabetes, but a review is not a promise of a prescription. For a first prescription your answers need to show clear indications and no contraindications, and the doctor may ask for measurements or recent results, recommend that you see a doctor in person, or decline. The medicine itself is dispensed only by a pharmacy. We do not promise a deadline.

How is tirzepatide different from semaglutide?

Tirzepatide acts on two receptors, GIP and GLP-1, while semaglutide acts on the GLP-1 receptor only, and the two have different dose steps. A difference in mechanism is not an automatic advantage for a given person: what suits you depends on what is being treated, your other conditions, tolerance and what has already been tried. That comparison belongs to the doctor who knows your results.